Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536976 · ClinicalTrials.gov registry record · Phase 4
Mirabegron in Parkinson Disease and Impaired Cognition
A Phase 4 study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT02536976 is a Phase 4 study that has completed, run by HealthPartners Institute. The registered enrollment target is 7 participants.
The verdict
NCT02536976, a Phase 4 study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile. Specifically, available anticholinergic medications have a high risk of cognitive side-effects, which preclude their use in PD patients with CI. PD can also cause a number of non-motor symptoms that are likely to be adversely affected by the currently available anticholinergic agents. Mirabegron is the first pharmacologic treatment which may not exacerbate CI, constipation, orthostatic hypotension (OH), somnolence, and dry mouth in PD.
Interventions
- DRUG Placebo
- DRUG mirabegron
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02536976
The ClinicalTrials.gov registry entry for NCT02536976 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HealthPartners Institute, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02536976 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02536976 about?
NCT02536976 is a clinical study titled "Mirabegron in Parkinson Disease and Impaired Cognition". There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile. Specifically, available anticholinergic medications have a high risk of cognitive side-effects, which preclude their use in PD patients with CI. ...
What is the current status of trial NCT02536976?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2015-12. Estimated completion is 2018-08-01.
What interventions are being tested in trial NCT02536976?
The interventions under investigation include: Placebo (DRUG), mirabegron (DRUG).
Who is sponsoring clinical trial NCT02536976?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.